Annually there are 200,000 new cases of brain cancer. Prognosis is dire: brain cancer in Australia is the second largest cause of death in the 0-14 age group, surpassed only by accidental drowning. It is the highest cause of death in 0-39 age group with a 5-year survival rate of 19%. Of the 120 types of brain cancer, glioblastoma multiforme is the most common primary brain tumour, the most lethal and difficult to treat. This study will examine the ability of a new compound to make glioblastoma cells more sensitive to radiation therapy. This data will provide a strong foundation for the pre-clinical evaluation of our new compound for the treatment of glioblastoma which traditionally carries a dire prognosis.
A new compound to improve the outcomes of brain cancer in children